MCID: RCT020
MIFTS: 48

Rectum Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Rectum Adenocarcinoma

MalaCards integrated aliases for Rectum Adenocarcinoma:

Name: Rectum Adenocarcinoma 12 15
Rectal Adenocarcinoma 12 6 17
Adenocarcinoma of Rectum 71

Classifications:



External Ids:

Disease Ontology 12 DOID:1996
NCIt 49 C9383
SNOMED-CT 67 254582000
UMLS 71 C0149978

Summaries for Rectum Adenocarcinoma

Disease Ontology : 12 A rectum cancer that derives from epithelial cells of glandular origin.

MalaCards based summary : Rectum Adenocarcinoma, also known as rectal adenocarcinoma, is related to mammary paget's disease and anal canal adenocarcinoma. An important gene associated with Rectum Adenocarcinoma is APOLD1 (Apolipoprotein L Domain Containing 1), and among its related pathways/superpathways are Endometrial cancer and Glioma. The drugs Neomycin and Metronidazole have been mentioned in the context of this disorder. Affiliated tissues include lymph node, colon and liver, and related phenotypes are Decreased cell migration and neoplasm

Related Diseases for Rectum Adenocarcinoma

Diseases related to Rectum Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 508)
# Related Disease Score Top Affiliating Genes
1 mammary paget's disease 31.0 KRT7 KRT20 EGFR
2 anal canal adenocarcinoma 30.8 KRT7 CDX2 APOLD1
3 anal squamous cell carcinoma 30.7 TP53 MLH1 APOLD1
4 appendix adenocarcinoma 30.6 KRT7 KRT20 KRAS HRAS CEACAM5 CDX2
5 cystadenoma 30.6 KRT7 KRT20 CEACAM5
6 squamous cell carcinoma 30.5 TP53 KRT7 HRAS EGFR CTNNB1 CEACAM5
7 rectum neuroendocrine neoplasm 30.5 KRT7 CDX2
8 fibroma 30.5 KRT7 KRAS CTNNB1
9 cystadenocarcinoma 30.5 TP53 KRT7 HRAS CEACAM5
10 exanthem 30.5 KRAS HRAS EGFR
11 large intestine adenocarcinoma 30.4 TP53 KRAS HRAS CTNNB1
12 penile cancer 30.4 TP53 KRAS HRAS EGFR
13 myeloma, multiple 30.3 TP53 KRAS HRAS EGFR CTNNB1
14 in situ carcinoma 30.3 TP53 HRAS EGFR CTNNB1
15 thyroid gland anaplastic carcinoma 30.3 TP53 HRAS EGFR CTNNB1
16 adenosquamous carcinoma 30.3 TP53 KRT7 KRAS EGFR CEACAM5
17 colon adenocarcinoma 30.3 TP53 MSH6 MLH1 KRT20 KRAS EGFR
18 angiosarcoma 30.3 TP53 KRT7 KRAS
19 adenocarcinoma 30.2 TP53 MSH6 MLH1 KRT7 KRT20 KRAS
20 mucinous adenocarcinoma 30.2 TP53 MLH1 KRT7 KRT20 KRAS EGFR
21 familial adenomatous polyposis 30.2 TP53 MSH6 MLH1 KRAS HRAS CTNNB1
22 papillary adenocarcinoma 30.2 TP53 KRT7 KRAS HRAS CEACAM5 CDX2
23 renal cell carcinoma, papillary, 1 30.2 TP53 KRT7 HRAS EGFR CTNNB1
24 cystic teratoma 30.1 TP53 KRT7 KRT20 KRAS CEACAM5 CDX2
25 clear cell renal cell carcinoma 30.1 TP53 KRT7 KRAS EGFR CTNNB1
26 intrahepatic cholangiocarcinoma 30.1 TP53 KRT7 KRT20 KRAS EGFR CTNNB1
27 leukemia, chronic myeloid 30.1 TP53 KRAS HRAS EGFR CTNNB1
28 basal cell carcinoma 30.1 TP53 KRT7 KRT20 EGFR CTNNB1 CEACAM5
29 anus cancer 30.1 TP53 KRT7 KRAS HRAS EGFR CAGE1
30 tubular adenocarcinoma 30.0 KRT7 KRT20 EGFR CTNNB1 CEACAM5 CDX2
31 rectum cancer 30.0 SCRT1 RAB11B MSH6 MLH1 KRT20 KRAS
32 cholangiocarcinoma 30.0 TP53 KRT7 KRT20 KRAS EGFR CTNNB1
33 lynch syndrome 30.0 TP53 SIL1 MSH6 MLH1 KRAS HRAS
34 ovarian cystadenocarcinoma 30.0 TP53 SLC25A16 KRAS HRAS EGFR CTNNB1
35 teratoma 29.9 TP53 KRT7 KRT20 KRAS CTNNB1 CEACAM5
36 adenoma 29.9 TP53 MSH6 MLH1 KRT7 KRT20 KRAS
37 bladder cancer 29.9 TP53 MLH1 KRT20 KRAS HRAS EGFR
38 pancreatic adenocarcinoma 29.8 TP53 MLH1 KRAS HRAS EGFR CTNNB1
39 lymphangioma 29.7 TP53 MLH1 KRAS HRAS EGFR CTNNB1
40 lung cancer susceptibility 3 29.5 TP53 SLC25A16 KRT7 KRT20 KRAS HRAS
41 signet ring cell adenocarcinoma 29.4 TP53 SIL1 MLH1 KRT7 KRT20 KRAS
42 gastric adenocarcinoma 29.4 TP53 MLH1 KRT7 KRT20 KRAS HRAS
43 colorectal adenocarcinoma 29.3 TP53 MSH6 MLH1 KRT7 KRT20 KRAS
44 rectum mucinous adenocarcinoma 11.3
45 large intestine lipoma 10.7 CEACAM5 APOLD1
46 lipoma of colon 10.7 CEACAM5 APOLD1
47 leukoplakia of penis 10.7 KRT7 CEACAM5
48 trachea carcinoma in situ 10.7 KRAS HRAS
49 mucoepidermoid esophageal carcinoma 10.7 TP53 CEACAM5
50 urachal adenocarcinoma 10.7 KRAS CEACAM5

Graphical network of the top 20 diseases related to Rectum Adenocarcinoma:



Diseases related to Rectum Adenocarcinoma

Symptoms & Phenotypes for Rectum Adenocarcinoma

GenomeRNAi Phenotypes related to Rectum Adenocarcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-3 8.62 EGFR HRAS

MGI Mouse Phenotypes related to Rectum Adenocarcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.23 CDX2 CTNNB1 EGFR HRAS KRAS MLH1

Drugs & Therapeutics for Rectum Adenocarcinoma

Drugs for Rectum Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 86)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Neomycin Approved, Vet_approved Phase 4 1404-04-2 8378
2
Metronidazole Approved Phase 4 443-48-1 4173
3 Anti-Infective Agents Phase 4
4 Anti-Bacterial Agents Phase 4
5 Antibiotics, Antitubercular Phase 4
6
Trioxsalen Approved Phase 2, Phase 3 3902-71-4 5585
7
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
8
Tegafur Approved, Investigational Phase 3 17902-23-7 5386
9
Promethazine Approved, Investigational Phase 3 60-87-7 4927
10
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
11 Anesthetics Phase 3
12 Angiogenesis Inhibitors Phase 3
13 Dihematoporphyrin Ether Phase 2, Phase 3
14 Hematoporphyrin Derivative Phase 2, Phase 3
15 Cola Phase 3
16 Antineoplastic Agents, Immunological Phase 3
17
Bevacizumab Approved, Investigational Phase 2 216974-75-3
18
Lenograstim Approved, Investigational Phase 2 135968-09-1
19
Melphalan Approved Phase 2 148-82-3 460612 4053
20
Methotrexate Approved Phase 2 59-05-2, 1959-05-2 126941
21
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
22
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
23
Gemcitabine Approved Phase 2 95058-81-4 60750
24
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
25
Simvastatin Approved Phase 2 79902-63-9 54454
26
Pembrolizumab Approved Phase 2 1374853-91-4
27
Selenium Approved, Investigational, Vet_approved Phase 2 7782-49-2
28
Metformin Approved Phase 2 657-24-9 14219 4091
29
Pancrelipase Approved, Investigational Phase 2 53608-75-6
30
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
31
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
32 Bryostatin 1 Investigational Phase 2 83314-01-6
33 Pancreatic Polypeptide Investigational Phase 2 59763-91-6
34
Veliparib Investigational Phase 2 912444-00-9 11960529
35 Molgramostim Investigational Phase 2 99283-10-0
36 Fluorodeoxyglucose F18 Phase 2
37 Immunoglobulins Phase 2
38 Antibodies Phase 2
39 Immunoglobulins, Intravenous Phase 2
40 Liver Extracts Phase 2
41 Folfirinox Phase 2
42 Antibodies, Monoclonal Phase 2
43 Hormones Phase 2
44 Alkylating Agents Phase 2
45 Hematinics Phase 2
46 Endothelial Growth Factors Phase 2
47 Immunoglobulin G Phase 2
48 Antifungal Agents Phase 2
49 Cyclosporins Phase 2
50 Folic Acid Antagonists Phase 2

Interventional clinical trials:

(show top 50) (show all 108)
# Name Status NCT ID Phase Drugs
1 Mechanical Bowel Preparation and Oral Antibiotics Versus Mechanical Bowel Preparation Only Prior Rectal Surgery - a Prospective, Randomized Controlled Trial Not yet recruiting NCT04281667 Phase 4 Oral Antibiotics;Placebo;Mechanical Bowel Preparation
2 A Phase III Randomised Study Of J-Pouch Coloanal Anastomosis Versus Side-To-End Coloanal Anastomosis After Preoperative Radiotherapy And Total Mesorectal Excision In Patients With Mid And Distal Rectal Cancer Unknown status NCT00070005 Phase 3
3 Prospective Randomized Clinical Trial for no Inferiority With Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery (TEM) Versus Total Mesorectal Excision in T2-T3s N0, M0 Rectal Cancer Unknown status NCT01308190 Phase 3 Capecitabine (Xeloda)
4 A Phase III, Randomized Study of Adjuvant Chemotherapy for Patients With Rectal Adenocarcinoma Who Achieved Suboptimal Response After Neoadjuvant Chemo-radiotherapy. Unknown status NCT01941979 Phase 3 5-FU, Capecitabine, Oxaliplatin, Leucovorin.
5 A Randomized Controlled Clinical Trial Comparing Oncological Results and Functional Recovery Between Laparoscopic and Open Method for the Treatment of Advanced Rectal Cancer After Concurrent Chemoradiation Therapy (CCRT) Unknown status NCT00601549 Phase 3
6 A Randomised Trial of Preoperative Radiotherapy for Stage T3 Adenocarcinoma of Rectum Completed NCT00145769 Phase 3 Short Course Adjuvent Chemotherapy;Long Course Adjuvant Chemotherapy;Concurrent Chemotherapy
7 GRECCAR 8 : Impact on Survival of the Primary Tumor Resection in Rectal Cancer With Unresectable Synchronous Metastasis a Randomized Multicenter Study Completed NCT02314182 Phase 3 Oxaliplatin/irinotecan + capecitabine, 5-FUI ± bevacizumab
8 Phase II Trial Comparing Two Neoadjuvant Treatments in Patients With Ultra-low Rectal Cancer: High-dose Radiotherapy Versus Radio-chemotherapy Completed NCT00979680 Phase 3
9 Estudo Randomizado de Fase II Com Capecitabina Versus 5-Fluorouracil/Leucovorin em Bolus Associados à Radioterapia no Tratamento Neoadjuvante de câncer de Reto Localmente avançado: INCAGI004. Completed NCT03428529 Phase 2, Phase 3 Capecitabine Oral Product;5Fluorouracil
10 European Phase III Study Comparing a Radiation Dose Escalation Using 2 Different Approaches : External Beam Radiation Therapy Versus Endocavitary Radiation Therapy With Contact X-ray Brachytherapy 50 kiloVolts (kV) for Patients With Rectal Adenocarcinoma Recruiting NCT02505750 Phase 3 Capecitabine
11 A Multicentric Randomised Trial to Evaluate Efficacy, Morbidity and Functional Outcome of Endoscopic TranAnal Proctectomy Versus Standard Transabdominal Laparoscopic Proctectomy for Low Lying Rectal Cancer (ETAP-GRECCAR 11) Recruiting NCT02584985 Phase 3
12 Longterm Outcome of Photodynamic Therapy Compared With Chemotherapy Alone in Patients With Advanced Rectal Cancer Suspended NCT01872104 Phase 2, Phase 3
13 Trial UFT/RT Randomized Multicenter Phase III Randomized Trial Testing Ftorafur (UFT) Associated With Neoadjuvant Radiotherapy Versus Radiotherapy Alone in Rectal Adenocarcinoma Terminated NCT00207831 Phase 3 Tegafur and Uracil
14 A Phase II Trial Of Irinotecan /5-FU/ Leucovorin Or Oxaliplatin /5-FU / Leucovorin With And Without Cetuximab (C225) For Patients With Untreated Metastatic Adenocarcinoma Of The Colon or Rectum Terminated NCT00077233 Phase 3 cetuximab;5-FU;irinotecan;leucovorin;oxaliplatin
15 Non-Operative Treatment for Rectal Cancer Following Complete Response to Neo-Adjuvant Therapy Unknown status NCT01047969 Phase 2 Adjuvant Chemotherapy
16 Local Excision of Clinical T3 Mid- or Low-Rectal Adenocarcinoma Showing Major Response(ycT0-1) After Neoadjuvant Chemoradiotherapy: Prospective Multicenter Single-arm Phase II Clinical Trial Unknown status NCT02490709 Phase 2
17 Treatment of Induction With XELOX-Bevacizumab in Locally Advanced Rectal Adenocarcinoma: Phase II Study Unknown status NCT00557713 Phase 2 bevacizumab
18 Phase II Study Of Radiotherapy And Capecitabine As Pre-Operative Treatment In Patients With Colorectal Cancer Unknown status NCT00075556 Phase 2 capecitabine
19 Efficacy and Safety of Neoadjuvant Chemo-chemoradio-chemo Sequential Therapy in Locally Advanced Mid/Low Rectal Cancer: a Phase II Trial Unknown status NCT02022852 Phase 2 Capecitabine;XELOX
20 Study of the Value of the PET/CT in Evaluating the Response of Distal Rectal Cancer to Neoadjuvant Chemoradiation Therapy Unknown status NCT00254683 Phase 2
21 ESTUDIO FASE II DE BEVACIZUMAB EN COMBINACIÓN CON CAPECITABINA Y RADIOTERAPIA COMO TRATAMIENTO PREOPERATORIO EN PACIENTES CON CÁNCER RECTAL LOCALMENTE AVANZADO RESECABLE Completed NCT00847119 Phase 2 capecitabine (Xeloda)
22 Phase II Trial of Neoadjuvant Chemoradiation With Bevacizumab for Chinese Locally Advanced Rectal Adenocarcinoma Completed NCT01554059 Phase 2 Bevacizumab;Oxaliplatin;5-FU
23 A Single-Arm Prospective Trial Evaluating The Local And Systemic Benefits Of Oxaliplatin And 5FU With Concurrent Radiation In Patients With Metastatic Rectal Cancer Completed NCT00422864 Phase 2 oxaliplatin;fluorouracil;leucovorin
24 Phase II: First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis Completed NCT01674309 Phase 2 FOLFORINOX
25 A Phase II Study Of Oral DJ-927 Administered As A Single Dose Every Three Weeks To Patients With Advanced Or Metastatic Adenocarcinoma Of The Colon Or Rectum Completed NCT00080834 Phase 2 DJ-927
26 Phase II Study of Bryostatin 1 in Patients With Metastatic Colo-Rectal Adenocarcinoma Completed NCT00003220 Phase 2 bryostatin 1
27 Open-label Phase II Study of Induction Treatment With Folfoxiri Plus Bevacizumab Followed by Preoperative Chemoradiotherapy Plus Bevacizumab in Patients With Locally Advanced, Resectable Rectal Cancer. Completed NCT03085992 Phase 2 FOLFOXIRI plus Bevacizumab
28 Frontline Chemotherapy "Reinforced" for Cancers of the Colon and Rectum With Potentially Resectable Hepatic and/or Pulmonary Metastases: Association of FOLFIRI and ERBITUX Completed NCT00557102 Phase 2 fluorouracil;irinotecan hydrochloride;leucovorin calcium
29 A Phase II Study Of Hepatic Arterial Infusion Of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) For Unresectable Primary And Metastatic Cancers Of The Liver Completed NCT00096083 Phase 2 isolated perfusion;melphalan
30 Phase II Study of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab in Patients With Locally Advanced Rectal Cancer Completed NCT00321685 Phase 2 Capecitabine;Fluorouracil;Leucovorin Calcium;Oxaliplatin
31 Exploratory Study of Non-Myeloablative Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusions for Metastatic Neoplasms Refractory to Standard Therapy Completed NCT00001880 Phase 2 methotrexate;cyclosporin
32 INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer, a Phase II Randomized Multi-center Trial of Neoadjuvant Therapy With and Without APX005M, an Anti-CD40 Agonist, APX005M, for Locally Advanced Rectal Adenocarcinoma Recruiting NCT04130854 Phase 2 Radiation Therapy 5Gy x 5 days
33 Phase II Study of Neo-adjuvant Chemoradiotherapy Using Infusional Gemcitabine Followed by Surgery for Locally Advanced (T3 and T4 or Node Positive) Rectal Adenocarcinoma Recruiting NCT02919878 Phase 2 Gemcitabine;capecitabine
34 A Phase II Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Rectal Adenocarcinoma Recruiting NCT04165772 Phase 2 TSR-042;capecitabine or 5-FU
35 Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma Recruiting NCT03503630 Phase 2 COMPOUND 2055269;mFOLFOX
36 Preoperative Radiochemotherapy With IMRT - Simultaneous Integrated Boost in Locally Advanced Rectal Cancer - BISER Recruiting NCT02268006 Phase 2 Capecitabine
37 Phase II Study of TGFβ Type I Receptor Inhibitor LY2157299 With Neoadjuvant Chemoradiation in Patients With Locally Advanced Rectal Adenocarcinoma Recruiting NCT02688712 Phase 2 LY2157299;Capecitabine;Fluorouracil
38 Preoperative Induction Therapy With 12 Weeks of Panitumumab in Combination With mFOLFOX-6 in an Enriched Population (Quadruple Wild-Type) of Patients With mrT3 Rectal Cancer of the Middle Third With Clear Mesorectal Fascia Recruiting NCT03000374 Phase 2 Panitumumab;5Fluorouracil;Oxaliplatin;Leucovorin
39 GI-116: Phase II Study of Organ Preservation in Early Rectal Cancer Patients Recruiting NCT03548961 Phase 2 FOLFOX regimen
40 A Single Arm, Phase II Study of Neoadjuvant Chemoradiotherapy With Capecitabine Plus Simvastatin in Locally Advanced Rectal Cancer Patients Active, not recruiting NCT02161822 Phase 2 simvastatin
41 Biomarkers and Clinical Outcomes in Localized Rectal Adenocarcinoma Treated With Neoadjuvant Therapy Not yet recruiting NCT04418895 Phase 2 mFOLFOX6;CAPOX;fluoropyrimidine +/- oxaliplatin
42 A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer Suspended NCT02921256 Phase 2 Capecitabine;Fluorouracil;Leucovorin;Oxaliplatin;Veliparib
43 Prospective Pilot Study of Multimodal Radiological Evaluation Feasibility During Chemoradiotherapy of Rectal Adenocarcinomas. Terminated NCT01619696 Phase 2
44 A Phase II Study of Capecitabine, Oxaliplatin and Selenomethionine and Radiation Therapy in Patients With Stage II and III Rectal Adenocarcinoma Terminated NCT00625183 Phase 2 capecitabine;oxaliplatin
45 Pilot Study: Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth Terminated NCT01632020 Phase 2 Placebo;Metformin
46 A Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of the Rectum Terminated NCT00580073 Phase 2 FOLFOX4;Cetuximab
47 Phase II Trial of Low Dose Whole Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX for Patients With Newly Diagnosed T3N0M0, T2N1M0, or T3N1M0 Rectal Adenocarcinoma Terminated NCT02319304 Phase 2 FOLFOX {5-fluorouracil (5-FU), leucovorin, and oxaliplatin}
48 Phase II Study of Capecitabine, Oxaliplatin and Cetuximab Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma Terminated NCT00353457 Phase 2 Capecitabine, Oxaliplatin and Cetuximab
49 A Phase II Trial Of Celecoxib (Celebrex) And Capecitabine (Xeloda) Combined With Pelvic Irradiation As Neoadjuvant Treatment Of Stage II or III Adenocarcinoma Of The Rectum Terminated NCT00081224 Phase 2 capecitabine;celecoxib
50 A Trial Of Vaccination With The Carcinoembryonic Antigen (CEA) Peptide Cap 1-6D With Montanide ISA 51 Adjuvant Or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) In HLA-A2+ Patients With CEA Producing Adenocarcinomas Of Gastrointestinal (GI) Tract Origin Terminated NCT00012246 Phase 2

Search NIH Clinical Center for Rectum Adenocarcinoma

Genetic Tests for Rectum Adenocarcinoma

Anatomical Context for Rectum Adenocarcinoma

MalaCards organs/tissues related to Rectum Adenocarcinoma:

40
Lymph Node, Colon, Liver, Testes, Prostate, Endothelial, T Cells

Publications for Rectum Adenocarcinoma

Articles related to Rectum Adenocarcinoma:

(show top 50) (show all 2027)
# Title Authors PMID Year
1
The Time Between Chemoradiation and Surgery for Rectal Carcinoma Negatively Influences Mesorectal Excision Quality. 61
31482400 2020
2
"Decision for adjuvant treatment in stage II colon cancer based on circulating tumor DNA:The CIRCULATE-PRODIGE 70 trial". 61
32482534 2020
3
Predicting Rectal Cancer Response to Neoadjuvant Chemoradiotherapy Using Deep Learning of Diffusion Kurtosis MRI. 61
32315264 2020
4
PSMA Expression in the Neovasculature Associated With Rectal Adenocarcinoma: A Potential Stromal Target for Nuclear Theranostics. 61
32404709 2020
5
Local versus Radical Excision of Early Distal Rectal Cancers: A National Cancer Database Analysis. 61
31898098 2020
6
miR-129-5p inhibits proliferation, migration, and invasion in rectal adenocarcinoma cells through targeting E2F7. 61
32052431 2020
7
Predictors of overall survival following extended radical resections for locally advanced and recurrent pelvic malignancies. 61
32533361 2020
8
Hybrid notes side-to-end ultra-low circular mechanical colorectal anastomosis during TaTME - video vignette. 61
32543014 2020
9
Seminal Vesicle Adherent to Rectal Wall Following Neoadjuvant Chemoradiotherapy: A Potential False-Positive Diagnostic Pitfall. 61
32008384 2020
10
The Coexistence of RAS and BRAF Mutations in Metastatic Colorectal Cancer: A Case Report and Systematic Literature Review. 61
32530992 2020
11
Neoadjuvant Treatment in Upper Rectal Cancer Does Not Improve Oncologic Outcomes But Increases Postoperative Morbidity. 61
32487661 2020
12
Long-term Oncological Outcomes Following Anastomotic Leak in Rectal Cancer Surgery. 61
32109914 2020
13
Robotic proctectomy for rectal cancer in the US: a skewed population. 61
31372887 2020
14
National postoperative and oncologic outcomes after pelvic exenteration for T4b rectal cancer. 61
32516469 2020
15
Juvenile polyposis syndrome might be misdiagnosed as familial adenomatous polyposis: a case report and literature review. 61
32487124 2020
16
Video Vignette: Laparoscopic pan-proctocolectomy with intersphincteric dissection and transanal TME for a mid-rectal cancer and MYH-associated polyposis. 61
32531103 2020
17
Preoperative chemoradiotherapy versus surgery alone for advanced low rectal cancer: a large multicenter cohort study in Japan. 61
32524272 2020
18
Functional outcomes over time following perineal pseudocontinent colostomy reconstruction after abdominoperineal resection for ultralow rectal adenocarcinoma. 61
32563198 2020
19
Endoscopic Ultrasound in an Adolescent With Rectal Adenocarcinoma and Lynch Syndrome. 61
32443053 2020
20
Fibroblast growth factor receptor-like-1: a new therapeutic target and unfavorable prognostic indicator for rectal adenocarcinoma. 61
32098557 2020
21
Editorial for "Comparative Analysis of Amide Proton Transfer MRI and Diffusion-Weighted Imaging in Assessing p53 and Ki-67 Expression of Rectal Adenocarcinoma". 61
32557898 2020
22
Comparative Analysis of Amide Proton Transfer MRI and Diffusion-Weighted Imaging in Assessing p53 and Ki-67 Expression of Rectal Adenocarcinoma. 61
32524685 2020
23
Validation of the Low Anterior Resection Syndrome Score in Finnish Patients: Preliminary Results on Quality of Life in Different Lars Severity Groups. 61
32552563 2020
24
Diagnostic accuracy of FDG-PET/MRI versus pelvic MRI and thoracic and abdominal CT for detecting synchronous distant metastases in rectal cancer patients. 61
32561971 2020
25
[Initial report of laparoscopic single incision plus one port with simultaneous robotic-assisted transanal total mesorectal excision for low rectal cancer surgery]. 61
32521984 2020
26
The tumour microenvironment of the upper and lower gastrointestinal tract differentially influences dendritic cell maturation. 61
32552799 2020
27
Pathologic Response and Postoperative Complications After Short-course Radiation Therapy and Chemotherapy for Patients With Rectal Adenocarcinoma. 61
32173279 2020
28
Association of Surgical Skill Assessment With Clinical Outcomes in Cancer Surgery. 61
32374371 2020
29
Laparoscopic Posterior Pelvic Exenteration (Complete and Supralevator) for Locally Advanced Adenocarcinoma of the Rectum in Females: Surgical Technique and Short-Term Outcomes. 61
31794331 2020
30
Clinical parameters predictive for sphincter-preserving surgery and prognostic outcome in patients with locally advanced low rectal cancer. 61
32375894 2020
31
Transanal Minimally Invasive Surgery: A Multi-Purpose Operation. 61
32219810 2020
32
Metastatic rectal cancer to papillary thyroid carcinoma: a case report and review of literature. 61
32375670 2020
33
Pan‑cancer analysis of transmembrane protease serine 2 and cathepsin L that mediate cellular SARS‑CoV‑2 infection leading to COVID-19. 61
32468052 2020
34
Genetic alteration, RNA expression, and DNA methylation profiling of coronavirus disease 2019 (COVID-19) receptor ACE2 in malignancies: a pan-cancer analysis. 61
32366279 2020
35
Predictive factors of complete pathological response in patients with locally advanced rectal cancer. 61
32474708 2020
36
Role of dynamic perfusion magnetic resonance imaging in patients with local advanced rectal cancer. 61
32523318 2020
37
Low rectal cancer treatment strategies: a cohort study assessing watch and wait. 61
32435893 2020
38
A cutaneous metastasis of unresectable rectal adenocarcinoma: A case report and literature review. 61
32446230 2020
39
Management of locally advanced synchronous colorectal and prostate cancers: A case report. 61
32481410 2020
40
A case of metastatic rectal adenocarcinoma diagnosed by thyroid cytology. 61
32364645 2020
41
Neoadjuvant Chemoradiotherapy and Tumor Recurrence in Patients with Early T-Stage Cancer of the Lower Rectum. 61
31773520 2020
42
The Clinical Relevance of Frequent Germline Genetic Variants Detected by Targeted Sequencing in Patients With Rectal Adenocarcinoma (READ). 61
32345670 2020
43
Evaluation of Transanal Minimally Invasive Surgery for Rectal Benign Lesions. 61
32251610 2020
44
Evaluating treatment protocols for rectal squamous cell carcinomas: the Duke experience and literature. 61
32399265 2020
45
Structural Insight into the Interactions between Structurally Similar Inhibitors and SIRT6. 61
32283646 2020
46
Risk factors for conversion in laparoscopic and robotic rectal cancer surgery. 61
31976558 2020
47
Risk factors and therapeutic significance of inguinal lymph node metastasis in advanced lower rectal cancer. 61
32009191 2020
48
Lymph Node Positivity in T1/T2 Rectal Cancer: a Word of Caution in an Era of Increased Incidence and Changing Biology for Rectal Cancer. 61
32246393 2020
49
Delayed surgery after radio-chemotherapy for rectal adenocarcinoma is protective for anastomotic dehiscence: a single-center observational retrospective cohort study. 61
32306273 2020
50
NRF3-POMP-20S Proteasome Assembly Axis Promotes Cancer Development via Ubiquitin-Independent Proteolysis of p53 and Retinoblastoma Protein. 61
32123008 2020

Variations for Rectum Adenocarcinoma

ClinVar genetic disease variations for Rectum Adenocarcinoma:

6 ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 APC NM_000038.6(APC):c.6152A>G (p.Lys2051Arg)SNV Uncertain significance 559958 rs1554087256 5:112177443-112177443 5:112841746-112841746
2 APC NM_000038.6(APC):c.3160C>T (p.His1054Tyr)SNV Uncertain significance 559960 rs1195583636 5:112174451-112174451 5:112838754-112838754
3 APC NM_000038.6(APC):c.811A>G (p.Met271Val)SNV Uncertain significance 141061 rs587781464 5:112137057-112137057 5:112801360-112801360
4 APC NM_000038.6(APC):c.1984C>A (p.Leu662Ile)SNV Uncertain significance 232098 rs756859993 5:112173275-112173275 5:112837578-112837578

Expression for Rectum Adenocarcinoma

Search GEO for disease gene expression data for Rectum Adenocarcinoma.

Pathways for Rectum Adenocarcinoma

Pathways related to Rectum Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.69 TP53 MSH6 MLH1 KRAS HRAS EGFR
2
Show member pathways
12.61 TP53 MSH6 KRAS HRAS EGFR
3 12.59 TP53 MSH6 MLH1 KRAS HRAS EGFR
4
Show member pathways
12.51 TP53 KRAS HRAS EGFR CTNNB1
5
Show member pathways
12.47 TP53 MLH1 KRAS HRAS EGFR CTNNB1
6
Show member pathways
12.43 TP53 KRAS HRAS EGFR CTNNB1
7
Show member pathways
12.33 TP53 KRAS HRAS EGFR CTNNB1
8
Show member pathways
12.25 TP53 HRAS EGFR CTNNB1
9
Show member pathways
12.24 KRAS HRAS EGFR CTNNB1
10
Show member pathways
12.23 TP53 KRAS HRAS EGFR
11 12.19 TP53 KRAS HRAS EGFR CTNNB1
12
Show member pathways
12.01 TP53 KRAS HRAS EGFR
13 11.95 TP53 MSH6 KRAS EGFR CTNNB1
14 11.93 TP53 KRAS HRAS CTNNB1
15 11.9 TP53 KRAS HRAS CTNNB1
16 11.76 KRAS HRAS EGFR
17 11.68 TP53 MSH6 MLH1
18 11.64 TP53 KRAS HRAS
19 11.62 TP53 KRAS HRAS EGFR
20 11.6 TP53 KRAS HRAS EGFR CTNNB1
21 11.58 TP53 KRAS HRAS EGFR
22 11.55 KRAS HRAS EGFR
23 11.46 KRAS HRAS EGFR
24 11.39 KRAS HRAS EGFR
25 11.32 TP53 MSH6 MLH1 KRAS EGFR CTNNB1
26 11.25 TP53 EGFR CTNNB1
27
Show member pathways
11.16 RAB1A KRAS HRAS
28
Show member pathways
11.09 KRAS HRAS EGFR
29 10.73 KRAS HRAS EGFR CTNNB1

GO Terms for Rectum Adenocarcinoma

Cellular components related to Rectum Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mismatch repair complex GO:0032300 8.62 MSH6 MLH1

Biological processes related to Rectum Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 liver development GO:0001889 9.61 KRAS HRAS EGFR
2 Ras protein signal transduction GO:0007265 9.5 TP53 KRAS HRAS
3 positive regulation of MAP kinase activity GO:0043406 9.43 KRAS HRAS EGFR
4 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.4 TP53 EGFR
5 regulation of protein localization to cell surface GO:2000008 9.37 RAB11B CTNNB1
6 response to isolation stress GO:0035900 9.16 KRAS HRAS
7 somatic recombination of immunoglobulin gene segments GO:0016447 8.96 MSH6 MLH1
8 intrinsic apoptotic signaling pathway GO:0097193 8.8 TP53 MSH6 HRAS

Molecular functions related to Rectum Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chromatin binding GO:0003682 9.65 TP53 MSH6 MLH1 EGFR CTNNB1
2 protein phosphatase binding GO:0019903 9.54 TP53 EGFR CTNNB1
3 enzyme binding GO:0019899 9.35 TP53 MSH6 MLH1 EGFR CTNNB1
4 GDP binding GO:0019003 9.33 RAB11B KRAS HRAS
5 mismatched DNA binding GO:0030983 9.32 MSH6 MLH1
6 guanine/thymine mispair binding GO:0032137 8.62 MSH6 MLH1

Sources for Rectum Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....